...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Japanese journal of clinical oncology. >Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
【24h】

Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.

机译：联合免疫疗法与小剂量IL-2加IFN-α联合治疗转移性肾细胞癌：对某些有肺转移和血清钠水平的患者的生存获益。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To clarify the survival benefit of immunotherapy for renal cell carcinoma patients with lung metastasis using low-dose interleukin-2 plus interferon-alpha, we examined survival outcomes and factors associated with prognosis. METHODS: This was a multicenter prospective study. Nephrectomized renal cell carcinoma patients with lung metastasis were treated with interleukin-2 (0.7 x 10(6) unit, 5 days a week) and interferon-alpha (6 x 10(6) IU, 3 days a week) for the first 8 weeks, and then with both interleukin-2 and interferon-alpha, 2 or 3 days a week for 16 additional weeks. RESULTS: Median follow-up period for 42 patients was 28.3 months (range: 4.2-43.8). Two-year overall survival rate was 82% and the probability of 3 year survival rate was 71%. Median progression-free survival was 10.4 months. While no difference was found in survival among patients assessed as complete response, partial response and no change, survival of patients assessed as NC or better was significantly better than those assessed as progressive disease (P < 0.0001). Furthermore, multivariate analyses identified pre-treatment serum sodium (P = 0.004) as an independent prognostic factor. The sodium level was also statistically associated with tumor response (p = 0.035). Patients with normal sodium level survived significantly longer (P = 0.0005) than those with low sodium level showing median survival of 12.2 months. CONCLUSIONS: Combination immunotherapy with low-dose interleukin-2 plus interferon-alpha showed survival benefit for patients with lung metastasis whose tumor responded as no change or better. This combination immunotherapy could be beneficial for patients selected by metastatic organ and their pre-treatment serum sodium level.
机译：目的：为阐明低剂量白细胞介素2加干扰素-α免疫疗法对肾细胞癌肺转移患者的生存获益，我们研究了生存结果和与预后相关的因素。方法：这是一项多中心前瞻性研究。肾转移性肾细胞癌肺转移患者在头8个月接受白细胞介素2（0.7 x 10（6）单位，一周5天）和干扰素-α（6 x 10（6）IU，一周3天）治疗一周，然后同时使用白介素2和干扰素-α，每周2或3天，共16周。结果：42例患者的中位随访期为28.3个月（范围：4.2-43.8）。两年总生存率为82％，三年生存率为71％。中位无进展生存期为10.4个月。虽然评估为完全缓解，部分缓解且无变化的患者的生存率无差异，但评估为NC或更好水平的患者的生存率显着高于评估为进行性疾病的患者（P <0.0001）。此外，多因素分析将治疗前血清钠（P = 0.004）确定为独立的预后因素。钠水平在统计学上也与肿瘤反应相关（p = 0.035）。钠水平正常的患者比中钠水平低的患者生存时间长得多（P = 0.0005），显示中位生存期为12.2个月。结论：小剂量白细胞介素2加干扰素-α联合免疫疗法对肺转移瘤患者的生存率有改善，其肿瘤反应无变化或好转。这种联合免疫疗法对转移器官选择的患者及其治疗前的血清钠水平可能是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号